07.11.16
Headquarters: Leverkusen, Germany
twitter.com/Bayer
www.bayerpharma.com
Headcount: 111,800
Year Established: 1971
Revenues: $50,611 (+12%)
Pharma Revenues: $15,017 (+13%)
Net Income: $4,490 (+20%)
R&D: $2,549 (+12%)
TOP SELLING DRUGS
Sales of Bayer’s pharmaceuticals segment climbed nearly 10 percent in 2015 driven by five recently launched products—Xarelto, Eylea, Stivarga, Xofigo and Adempas.
At the end of the year, the company established its new Bayer Life Science Center. This strategic innovation unit has been designed to help uncover, encourage and unlock breakthrough cross-species technologies and know-how for Bayer by enabling collaborations with entrepreneurial best-in-class companies. The first of these partnerships is a joint venture with Crispr Therapeutics AG, a company specialized in utilizing the new crispr-cas9 gene editing technology.
The partnership will focus on the discovery, development and commercialization of therapeutics for blood disorders, blindness and congenital heart disease. Crispr Therapeutics will contribute its crispr-cas9 gene-editing technology and intellectual property, while Bayer will provide protein engineering expertise and relevant disease knowledge.
The joint venture will be based in London, UK, with operations in Cambridge, MA. This long-term strategic partnership represents the first of its kind investment in the development of target delivery systems in an effort to bring systemic in vivo crispr-cas9 gene editing technology applications to patients.
This is the first investment by the newly established Bayer LifeScience Center, which operates as a strategic innovation unit within Bayer aimed at discovering scientific and medical breakthroughs more rapidly by enabling innovative partnerships. Bayer will provide a minimum of $300 million in R&D investments during the next five years and will acquire a minority stake in Crispr Therapeutics for $35 million.
During the year Bayer and The Johns Hopkins University entered into a five-year collaboration agreement to develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt’s disease, and retinal vein occlusion (RVO).
Bayer also licensed a thrombosis drug from Ionis and as part of the deal will assume clinical development and commercialization of it as well. The deal relates to Isis-FXIRx, an antisense investigational drug in development for the prevention of thrombosis. Bayer will further develop and commercialize Isis-FXIRx in areas of high unmet medical need.
Bayer HealthCare and Aronora entered a strategic alliance to manufacture Aronora’s AB-022 compound for the treatment of cardiovascular diseases.
In other news, Bayer unveiled plans to invest $100 million in its Berkeley, CA manufacturing site to build a product testing facility that will support the next generation of treatments for hemophilia A.
twitter.com/Bayer
www.bayerpharma.com
Headcount: 111,800
Year Established: 1971
Revenues: $50,611 (+12%)
Pharma Revenues: $15,017 (+13%)
Net Income: $4,490 (+20%)
R&D: $2,549 (+12%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Xarelto | atrial fibrillation | $2,460 | 34% |
Eylea | macular degeneration | $1,342 | 62% |
Kogenate | hemophilia | $1,262 | 4% |
Mirena | women’s health | $1,058 | 18% |
Nexavar | oncolgy | $975 | 15% |
Betaferon | multiple sclerosis | $900 | flat |
Yaz | women’s health | $771 | -8% |
Adalat | hypertension | $692 | 8% |
Aspirin | Cardio cardiovascular | $572 | 8% |
Glucobay | diabetes | $571 | 18% |
Sales of Bayer’s pharmaceuticals segment climbed nearly 10 percent in 2015 driven by five recently launched products—Xarelto, Eylea, Stivarga, Xofigo and Adempas.
At the end of the year, the company established its new Bayer Life Science Center. This strategic innovation unit has been designed to help uncover, encourage and unlock breakthrough cross-species technologies and know-how for Bayer by enabling collaborations with entrepreneurial best-in-class companies. The first of these partnerships is a joint venture with Crispr Therapeutics AG, a company specialized in utilizing the new crispr-cas9 gene editing technology.
The partnership will focus on the discovery, development and commercialization of therapeutics for blood disorders, blindness and congenital heart disease. Crispr Therapeutics will contribute its crispr-cas9 gene-editing technology and intellectual property, while Bayer will provide protein engineering expertise and relevant disease knowledge.
The joint venture will be based in London, UK, with operations in Cambridge, MA. This long-term strategic partnership represents the first of its kind investment in the development of target delivery systems in an effort to bring systemic in vivo crispr-cas9 gene editing technology applications to patients.
This is the first investment by the newly established Bayer LifeScience Center, which operates as a strategic innovation unit within Bayer aimed at discovering scientific and medical breakthroughs more rapidly by enabling innovative partnerships. Bayer will provide a minimum of $300 million in R&D investments during the next five years and will acquire a minority stake in Crispr Therapeutics for $35 million.
During the year Bayer and The Johns Hopkins University entered into a five-year collaboration agreement to develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt’s disease, and retinal vein occlusion (RVO).
Bayer also licensed a thrombosis drug from Ionis and as part of the deal will assume clinical development and commercialization of it as well. The deal relates to Isis-FXIRx, an antisense investigational drug in development for the prevention of thrombosis. Bayer will further develop and commercialize Isis-FXIRx in areas of high unmet medical need.
Bayer HealthCare and Aronora entered a strategic alliance to manufacture Aronora’s AB-022 compound for the treatment of cardiovascular diseases.
In other news, Bayer unveiled plans to invest $100 million in its Berkeley, CA manufacturing site to build a product testing facility that will support the next generation of treatments for hemophilia A.